Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/340458
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampPaula, Eneida de-
dc.typeArtigopt_BR
dc.titlePreclinical evaluation of ropivacaine in 2 liposomal modified systemspt_BR
dc.contributor.authorCarolina C., Rennó,-
dc.contributor.authorJuliana Z. B., Papini,-
dc.contributor.authorSaia, Cereda, Cintia Maria-
dc.contributor.authorElizabeth, Martinez,-
dc.contributor.authorAngelo, Montalli, Victor-
dc.contributor.authorEneida, de Paula,-
dc.contributor.authorJosé, Pedrazzoli Júnior,-
dc.contributor.authorAparecida, Calafatti, Silvana-
dc.contributor.authorRadomille, Tofoli, Giovana-
dc.subjectAvaliaçãopt_BR
dc.subjectRopivacaínapt_BR
dc.subject.otherlanguageEvaluationpt_BR
dc.subject.otherlanguageRopivacainept_BR
dc.description.abstractOur research group has recently developed liposomes with ionic gradient and in a combined manner as donor and acceptor vesicles containing ropivacaine (RVC; at 2% or 0.75%). Looking for applications of such novel formulations for postoperative pain control, we evaluated the duration of anesthesia, pharmacokinetics, and tissue reaction evoked by these new RVC formulations. The formulations used in this study were large multivesicular vesicle (LMVV) containing sodium acetate buffer at pH 5.5 or in a combined manner with LMVV as donor and large unilamellar vesicles (LUVs) as acceptor vesicles with an external pH of 7.4. Wistar rats were divided into 6 groups (n = 6) and received sciatic nerve block (0.4 mL) with 6 formulations of RVC (LMVVRVC0.75%, LMVV/LUVRVC0.75%, LMVVRVC2%, LMVV/LUVRVC2%, RVC 0.75%, and RVC 2%). To verify the anesthetic effect, the animals were submitted to the pain pressure test and the motor block was also monitored. Histopathology of the tissues surrounding the sciatic nerve region was also assessed 2 and 7 days after treatment. Rats (n = 6) were submitted to a hind paw incision, and mechanical hypersensitivity was measured via the withdrawal response using von Frey filaments after injection of the 6 formulations. Finally, New Zealand white rabbits (n = 6) received sciatic nerve block (3 mL) with 1 of the 6 formulations of RVC. Blood samples were collected predose (0 minutes) and at 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420, 480, and 540 minutes after injection. RVC plasma levels were determined using a triple-stage quadrupole mass spectrometer. Duration and intensity of the sensory block were longer with all liposomal formulations, when compared to the plain RVC solution (P < .05). Histopathological evaluation showed greater toxicity for the positive control (lidocaine 10%), when compared to all formulations (P < .05). After the hind paw incision, all animals presented postincisional hypersensitivity and liposomal formulations showed longer analgesia (P < .05). LMVVRVC0.75% presented higher time to reach maximum concentration and mean residence time than the remaining formulations with RVC 0.75% (P < .05), so LMVV was able to reduce systemic exposure of RVC due to slow release from this liposomal system. All new liposomal formulations containing 0.75% RVC were able to change the pharmacokinetics and enhance anesthesia duration due to slow release of RVC from liposomes without inducing significant toxic effects to local tissuespt_BR
dc.relation.ispartofAnesthesia and analgesiapt_BR
dc.relation.ispartofabbreviationAnesth analgpt_BR
dc.publisher.cityCleveland, OHpt_BR
dc.publisher.countryEstados Unidospt_BR
dc.publisherLippincott Williams & Wilkins pt_BR
dc.date.issued2019-08-
dc.date.monthofcirculationAug.pt_BR
dc.language.isoengpt_BR
dc.description.volume129pt_BR
dc.description.issuenumber2pt_BR
dc.description.firstpage387pt_BR
dc.description.lastpage396pt_BR
dc.rightsFechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn0003-2999pt_BR
dc.identifier.eissn1526-7598pt_BR
dc.identifier.doi10.1213/ANE.0000000000003837pt_BR
dc.identifier.urlhttps://journals.lww.com/anesthesia-analgesia/fulltext/2019/08000/preclinical_evaluation_of_ropivacaine_in_2.16.aspxpt_BR
dc.description.sponsorshipFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPpt_BR
dc.description.sponsordocumentnumber2014/14457-5pt_BR
dc.date.available2020-05-08T18:00:03Z-
dc.date.accessioned2020-05-08T18:00:03Z-
dc.description.provenanceSubmitted by Susilene Barbosa da Silva (susilene@unicamp.br) on 2020-05-08T18:00:03Z No. of bitstreams: 0. Added 1 bitstream(s) on 2020-08-27T19:16:39Z : No. of bitstreams: 1 000475951100028.pdf: 885874 bytes, checksum: 86a2ec35f22d1299904b50820a64f036 (MD5)en
dc.description.provenanceMade available in DSpace on 2020-05-08T18:00:03Z (GMT). No. of bitstreams: 0 Previous issue date: 2019-08en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/340458-
dc.contributor.departmentDepartamento de Bioquímica e Biologia Tecidualpt_BR
dc.contributor.unidadeInstituto de Biologiapt_BR
dc.subject.keywordLiposomal Modified Systemspt_BR
dc.identifier.source000475951100028pt_BR
dc.creator.orcid0000-0003-4504-5723pt_BR
dc.type.formArtigopt_BR
dc.description.sponsorNoteThe authors are grateful to Cristália Produtos Químicos Farmacêuticos Ltda (SP, Brazil) for the donation of ropivacaine (RVC) and Fundação de Amparo á Pesquisa do Estado de São Paulo (No. 2014/14457-5) for the financial support. The authors thank Dr Marcelo Sperandio for his kind contribution to this manuscript. The authors also thank Mr Fabio Saia Cereda for his contribution in the statistical analysispt_BR
Appears in Collections:IB - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000475951100028.pdf865.11 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.